India Biosimilar Market Growth 2025-2033: Size, Share, Industry Trends, Growth Rate & Forecast

Biosimilar Market - India

Market Statistics

Base Year: 2024

Historical Years: 2019-2024

Forecast Years: 2025-2033

Market Size in 2024: USD 866.2 Million

Market Size in 2033: USD 3,662.9 Million

Market Growth Rate (CAGR) 2025-2033: 17.38%

According to IMARC Group's report titled "India Biosimilar Market Report and Forecast 2025-2033," the market reached USD 866.2 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 3,662.9 Million by 2033, exhibiting a growth rate (CAGR) of 17.38% during 2025-2033.

Download sample copy of the Report: https://www.imarcgroup.com/india-biosimilar-market/requestsample

India Biosimilar Market Trends and Drivers:

• The India biosimilar market is growing at a quick pace driven by a mix of heightened demand for affordable biologic therapies as well as soaring incidence of chronic conditions like cancer, diabetes, and autoimmune diseases.
• Moreover, efforts by governments to cut healthcare expenditure and enhance access to vital medicine have generated a conducive regulatory and financing environment for the development and sales of biosimilars.
• Additionally, advancements in biomanufacturing technologies and infrastructure are fortifying local capabilities, allowing Indian manufacturers to make competitive cost biosimilar molecules of high quality.
• Essentially, partnerships among Indian biotech companies, research institutions, and international pharmaceutical players are propelling product pipelines and promoting innovation in biosimilar development.
• Apart from this, simplified regulations and approval processes through the Central Drugs Standard Control Organization (CDSCO) have brought time to market down, facilitating a rapid release of several biosimilars across therapeutic categories.
• Moreover, increasing healthcare insurance penetration and growing hospital networks in tier‑2 and tier‑3 cities have increased patient access, thereby directly impacting biosimilar penetration.
• In addition, collaboration in marketing and distribution strategies between Indian companies and multinational drug makers is expanding market coverage and increasing physician trust in biosimilars.
• Essentially, price-sensitive hospital purchasing and tendering are also benefiting biosimilars through significant discounts over originator biologics, spurring institutional uptake.
• Furthermore, greater physician knowledge and awareness campaigns regarding biosimilar safety and efficacy have started to mitigate reluctance, promoting prescribing confidence.
• Additionally, increasing emphasis on biosimilars for oncology, rheumatology, and endocrinology therapeutics is expanding the drug pipeline and enriching treatment options for patients.
• In addition, venture capital funds and government-aided funds are driving R&D, enabling Indian biosimilar developers to expand facilities and push clinical trials.
• In short, the U-shaping of robust domestic manufacturing capacities, good regulation regimes, strategic partnerships, and expanding healthcare needs is making India a worldwide biosimilar hub for continued growth.

India Biosimilar Market Segmentation:

We explore the factors propelling the India biosimilar market growth, including technological advancements, consumer behaviors, and regulatory changes.

Molecule Insights:

• Infliximab
• Insulin Glargine
• Epoetin Alfa
• Etanercept
• Filgrastim
• Somatropin
• Rituximab
• Follitropin Alfa
• Adalimumab
• Pegfilgrastim
• Trastuzumab
• Bevacizumab
• Others

Indication Insights:

• Auto-Immune Diseases
• Blood Disorder
• Diabetes
• Oncology
• Growth Deficiency
• Female Infertility
• Others

Manufacturing Type Insights:

• In-house Manufacturing
• Contract Manufacturing

Regional Insights:

• North India
• West and Central India
• South India
• East and Northeast India

Request for customization: https://www.imarcgroup.com/request?type=report&id=21512&flag=C

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Key highlights of the Report:

• Market Performance (2019-2024)
• Market Outlook (2025-2033)
• COVID-19 Impact on the Market
• Porter’s Five Forces Analysis
• Strategic Recommendation
• Historical, Current and Future Market Trends
• Market Drivers and Success Factors
• SWOT Analysis
• Structure of the Market
• Value Chain Analysis
• Comprehensive Mapping of the Competitive Landscape

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:  

IMARC Group 

134 N 4th St. Brooklyn, NY 11249, USA 

Email: sales@imarcgroup.com 

Tel No:(D) +91 120 433 0800 

United States: +1-631-791-1145